Shares of Replimune Group REPL have surged 131.1% over the past three months, fueled by positive regulatory updates. In ...

In July, the FDA issued a complete response letter (CRL) for Replimune's biologics license application for RP1 (vusolimogene ...

The Food and Drug Administration on Friday approved a new cancer therapy that could one day transform the way a majority of aggressive and advanced tumors are treated. The treatment, called Amtagvi, ...

Please provide your email address to receive an email when new articles are posted on . Combining lifileucel plus pembrolizumab conferred a complete response in nearly one-third of patients with ...

Please provide your email address to receive an email when new articles are posted on . Nivolumab significantly improved RFS for advanced melanoma compared with ipilimumab after 9 years of follow-up.

CLEVELAND — We love the sun in Northeast Ohio, but we also need to respect it. Too much of it — too many sunburns, too much time unprotected — can be dangerous and potentially lead to skin cancer.

The U.S. Food and Drug Administration (FDA) has approved a new type of cell-based therapy for people with advanced melanoma, and it may one day open up new treatment options for people with a wide ...

Rick Schneider is a family man — a husband and doting father to three girls. He's also an outdoorsman who loves to bike, hike and ski. There's no mountain he's not ready to climb. But a few years back ...

Dendritic cell activates T cells which in turn trigger immune responses. Amtagvi is the first first FDA-approved T cell therapy for a solid tumor indication. Based on Phase 2 data, the Food and Drug ...

Herpes is a common virus that is getting a rebrand from University of Southern California researchers who are using it to treat stubborn advanced cancer. Herpes has been called “the gift that keeps on ...